Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2025-04-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 27th meeting of the 5th Board of Directors of the company. It includes approvals of various reports such as the 2024 Annual Report, ESG Report, General Manager's Report, Board Work Report, Financial Statements, Profit Distribution Plan, and the 2025 Q1 Report. The document also mentions that these reports are disclosed separately on the official disclosure website (cninfo.com.cn) and that the resolutions will be submitted to the 2024 Annual General Meeting for approval. The document is a formal board meeting resolution announcement rather than the reports themselves. It contains detailed voting results and descriptions of agenda items but does not include the full financial statements or the full text of the reports. Therefore, it is best classified as Board/Management Information (MANG), which covers announcements of board decisions and management matters. The document length (5916 characters) and content confirm it is not a brief report publication announcement or a full annual report but a board meeting resolution announcement.
2025-04-15 Chinese
关于调整公司第五届董事会审计委员会成员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the adjustment of members of the company's fifth board audit committee. It details changes in board committee membership and governance structure but does not contain financial statements, audit reports, or detailed financial data. It is a formal disclosure about board/committee changes, which fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full audit report or annual report.
2025-04-15 Chinese
2024年度证券与衍生品投资情况专项报告
Regulatory Filings Classification · 90% confidence The document is titled as a "2024年度证券与衍生品投资情况专项报告" which translates to "2024 Annual Securities and Derivatives Investment Special Report." It details the company's securities and derivatives investment activities, including foreign exchange hedging business, risk analysis, risk management measures, and independent director review opinions. The document is relatively short (2130 characters) and focuses on a specific topic related to securities and derivatives investment rather than a full financial report or earnings release. It is not an announcement of a report publication but a standalone special report on investment activities and risk management. This type of document does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specialized report on securities and derivatives investment activities, which aligns best with the category "Regulatory Filings (RNS)" as a fallback for miscellaneous regulatory or compliance-related reports that do not fit other categories. Given the specificity and regulatory nature, but lack of a more precise category, RNS is the most appropriate classification with high confidence.
2025-04-15 Chinese
关于2025年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (439 characters) about the disclosure of the company's 2025 first quarter report. It states that the first quarter report has been approved and will be disclosed on a regulatory website. The document itself does not contain the actual financial data or the report content, but only informs investors about the upcoming report publication. According to the 'MENU VS MEAL' rule, such a short notice announcing the availability of a report is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2025-04-15 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by the company, referencing new accounting standards issued by the Ministry of Finance of China. It details the nature of the changes, their implementation dates, and the impact on financial statement line items. The document is relatively short (1559 characters) and does not contain full financial statements or comprehensive financial analysis. It is not a full annual or interim report but a regulatory announcement about accounting policy changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific report types.
2025-04-15 Chinese
2024年度独立董事述职报告（徐焱军）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from a specific independent director of the company. It details the director's attendance at board and shareholder meetings, committee work, communication with auditors, and oversight activities during the year 2024. The content focuses on the director's duties, governance, and compliance with laws and regulations, rather than presenting financial statements or audit results. It is a detailed report on board/management activities and governance oversight by an independent director, not an annual report, audit report, or other financial filing. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2025-04-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.